Clinical Trials
103
Active:0
Completed:71
Trial Phases
5 Phases
Early Phase 1:2
Phase 1:7
Phase 2:14
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (63 trials with phase data)• Click on a phase to view related trials
Not Applicable
20 (31.7%)Phase 3
20 (31.7%)Phase 2
14 (22.2%)Phase 1
7 (11.1%)Early Phase 1
2 (3.2%)Early Recurrence of Renal Colic: Predictive Factors
Completed
- Conditions
- Renal ColicEmergency Department Patient
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 878
- Registration Number
- NCT06982430
- Locations
- 🇹🇳
Nouira Semir, Monastir, Tunisia
Comparative Efficacy of IV Dexamethasone vs. Nebulized Salbutamol for Renal Colic Pain in the ED
Phase 3
Not yet recruiting
- Conditions
- Renal Colic
- Interventions
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 300
- Registration Number
- NCT06980727
Effect of Colloids Versus Crystalloids on Heart Mechanics: a Double-blind Cross Over Randomized Trial
Phase 3
- Conditions
- Fluid TherapyFluid ReponsivenessFluid Resuscitation
- Interventions
- Drug: GelafundinDrug: Saline (NaCl 0,9 %) (placebo)
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 16
- Registration Number
- NCT06900972
- Locations
- 🇹🇳
Fattouma Bourguiba Hospital, MOnastir, Tunisia
Effect of Cervical Traction on Balance in Cervical Radiculopathy
Not Applicable
Completed
- Conditions
- Cervical RadiculopathyBalance Disorders
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 36
- Registration Number
- NCT06727747
- Locations
- 🇹🇳
Faculty of Medicine of Monastir, Monastir, Tunisia
Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome
Phase 2
Not yet recruiting
- Conditions
- Acute Coronary Syndrome (ACS)Reactive HyperemiaEndothelial Dysfunction
- Interventions
- Drug: Placbo_AtheroliveDrug: Atherolive 500mg/dayDrug: Atherolive 1000/day
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 300
- Registration Number
- NCT06723002
- Prev
- 1
- 2
- 3
- 4
- 5
- 21
- Next
News
No news found